The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Open accessAbstract
Lysosomal storage diseases (LSDs) are a group of genetic disorders due to defects in any aspect of lysosomal biology. During the past two decades, different approaches have been introduced for the treatment of these conditions. Among them, enzyme replacement therapy (ERT) represented a major advance and is used successfully in the treatment of some of these disorders. However, ERT has limitations such as insufficient biodistribution of recombinant enzymes and high costs. An emerging strategy for the treatment of LSDs is pharmacological chaperone therapy (PCT), based on the use of chaperone molecules that assist the folding of mutated enzymes and improve their stability and lysosomal trafficking. After proof-of-concept studies, PCT is now being translated into clinical applications for Fabry, Gaucher and Pompe disease. This approach, however, can only be applied to patients carrying chaperone-responsive mutations. The recent demonstration of a synergistic effect of chaperones and ERT expands the applications of PCT and prompts a re-evaluation of their therapeutic use and potential. This review discusses the strengths and drawbacks of the potential therapies available for LSDs and proposes that future research should be directed towards the development of treatment protocols based on the combination of different therapies to improve the clinical outcome of LSD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Quality control in the endoplasmic reticulum
Ellgaard, L., & Helenius, A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1052 · Cited by 2,126
Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105233242104 · Cited by 1,252
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
The cell biology of lysosomal storage disorders
Futerman, A. H., & van Meer, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1423 · Cited by 796
van der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
Fan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study
Patterson, M. C., Vecchio, D., Prady, H., Abel, L., & Wraith, J. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70194-1 · Cited by 608
Lysosomal disorders: From storage to cellular damage
Ballabio, A., & Gieselmann, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.12.001 · Cited by 571
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
Cited by
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
Emerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
Lysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
Self-citationStructure of human lysosomal acid α-glucosidase–a guide for the treatment of Pompe disease
Roig-Zamboni, V., Cobucci-Ponzano, B., Iacono, R., Ferrara, M. C., Germany, S., Bourne, Y., Parenti, G., Moracci, M., & Sulzenbacher, G. (2017) · Nature Communications · doi:10.1038/s41467-017-01263-3 · Cited by 317
Self-citationUbiquitin and membrane protein turnover: from cradle to grave
MacGurn, J. A., Hsu, P.-C., & Emr, S. D. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060210-093619 · Cited by 287
Metadata
- Authors
- Parenti, G.
- Venue
- EMBO Molecular Medicine
- Published
- 2009-08
- Volume
- 1
- Issue
- 5
- Pages
- 268-279
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2116313758
- Cited by
- 273
- References
- 67
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. https://app.cochat.ai/papers/10.1002/emmm.200900036
- The paper
- Parenti, G. (2009). Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.200900036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.